Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2023-06-23 Audit Report / Informat…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Sprawozdanie_Rady_Nadzorczej_Celon_Pharma_SA_za_2022.pdf
Audit Report / Information Classification · 1% confidence The document is titled "SPRAWOZDANIE RADY NADZORCZEJ CELON PHARMA S.A." (Supervisory Board Report of Celon Pharma S.A.) for the financial year 2022, prepared in accordance with the Polish Commercial Companies Code (KSH) and Good Practices for Companies Listed on the WSE 2021. The content details the activities of the Supervisory Board, its composition, evaluations of the financial statements and management activity, internal control systems, and dividend proposals. This structure strongly indicates a formal report issued by the supervisory body concerning the past fiscal year's oversight and performance evaluation, which aligns best with the general category of an Audit Report/Information (AR) or potentially a component of an Annual Report, but since it is specifically the Supervisory Board's report on oversight and evaluation, and not the full 10-K, 'AR' is the most appropriate fit among the provided options for a comprehensive oversight report. It is a full report (30k+ characters), not a short announcement, so RPA/RNS is ruled out based on the 'MENU VS MEAL' rule. FY 2022
2023-06-23 Polish
Sprawozdanie_o_wynagrodzeniach_Czlonkow_Zarzadu_i_RN_Celon_Pharma_SA_za_2022.pdf
Remuneration Information Classification · 1% confidence The document title is "SPRAWOZDANIE O WYNAGRODZENIACH CZŁONKÓW ZARZĄDU I RADY NADZOR-CZEJ CELON PHARMA S.A. ZA OKRES 01.01.2022.-31.12.2022." (Report on Remuneration of Management Board and Supervisory Board Members of Celon Pharma S.A. for the period 01.01.2022-31.12.2022). The content details the composition of the Management Board and Supervisory Board, the structure and amounts of remuneration paid to these members for the fiscal year 2022, and compares these figures over the last five years. This content directly corresponds to the definition of a Remuneration Information report, which maps to the code DEF 14A (Proxy Solicitation & Information Statement often includes remuneration details, but DEF 14A specifically covers executive compensation reports in the US context, and given the specific focus on remuneration, it is the best fit among the provided options, especially since the Polish equivalent often aligns with proxy/governance disclosures). Reviewing the definitions, 'Remuneration Information (Code: DEF 14A)' is the most precise match for a detailed report on executive and board compensation.
2023-06-23 Polish
Uchwały podjęte przez Zwyczajne Walne Zgromadzenie Celon Pharma S.A. w dniu 22 czerwca 2023 r. - Content (PL)
AGM Information Classification · 1% confidence The document text is very short (829 characters) and explicitly states that the Management Board ('Zarząd') is enclosing the content of resolutions ('treść uchwał') adopted by the Annual General Meeting ('Zwyczajne Walne Zgromadzenie Spółki') held on June 22, 2023. It also mentions the approval of the Supervisory Board Report and the Remuneration Report during the meeting. Since the document is an announcement transmitting the results and related materials from the AGM, and not the full AGM presentation itself, it strongly aligns with the category for official results from shareholder votes. The most specific category is Declaration of Voting Results & Voting Rights Announcements (DVA). Although it mentions AGM resolutions, the core content being transmitted is the outcome of the voting process.
2023-06-23 Polish
Uchwała Zwyczajnego Walnego Zgromadzenia Spółki w sprawie w sprawie pokrycia straty oraz wypłaty dywidendy za rok obrotowy 2022 - Content (PL)
AGM Information Classification · 1% confidence The document text, written in Polish, explicitly states that the Annual General Meeting ('Zwyczajne Walne Zgromadzenie') held on June 22, 2023, passed a resolution regarding the coverage of the net loss and the payment of a dividend for the fiscal year 2022. The key action described is the decision to pay a dividend of PLN 0.09 per share, setting the record date and payment date. This directly corresponds to the definition of a 'Notice of Dividend Amount' (DIV). Although it mentions the AGM, the core content is the dividend declaration, not the AGM presentation itself (AGM-R) or the voting results (DVA). The document is short and contains the final decision, making DIV the most appropriate classification.
2023-06-22 Polish
Oświadczenie KDPW o dokonaniu asymilacji 21.500 akcji serii C z akcjami Spółki znajdującymi się w obrocie giełdowym - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document text, written in Polish, announces an action by the Management Board ('Zarząd') regarding the assimilation (integration) of 21,500 Series C shares into the existing publicly traded shares, effective June 19, 2023. This action fulfills a condition set by the Warsaw Stock Exchange (GPW) for introducing these shares to public trading. This is a direct announcement concerning a change in the company's capital structure (the listing/trading of new shares). This aligns best with the 'Share Issue/Capital Change' category (SHA), as it deals with the formal introduction of shares into the market.
2023-06-16 Polish
Dopuszczenie i wprowadzenie 21.500 akcji zwykłych na okaziciela serii C Spółki do obrotu giełdowego - Content (PL)
Regulatory Filings Classification · 1% confidence The document text, written in Polish, announces a resolution by the Management Board of the Warsaw Stock Exchange (GPW) dated June 13, 2023, regarding the admission and introduction of Series C ordinary bearer shares of Celon Pharma S.A. into stock exchange trading. It specifies the number of shares (21,500) and the effective date for trading (June 19, 2023), contingent on assimilation by KDPW. This is a formal announcement concerning the listing and trading status of company shares, which falls under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Since it deals directly with the admission of new shares to the main market, 'CAP' (Capital/Financing Update) is the most specific fit, as it relates to the capital structure being made available for public trading. Given the short length and the nature of the announcement (a formal regulatory action regarding listing), it is not a full report.
2023-06-14 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.